Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders.
Alemtuzumab is effective therapy for B- and T-cell lymphoproliferative disorders (LPD) but is associated with prolonged lymphopenia. Myeloid haematological toxicities are less well described, especially in T-cell disorders, and are usually transient. We report myeloid toxicities in a phase II trial of alemtuzumab for T-cell LPD. Five of 11 patients treated developed severe neutropenia and thrombocytopenia. Three cases had prolonged cytopenias (32-88+ weeks), including two with severe marrow hypoplasia. We observed three incidences of trilineage morphological myelodysplasia, two with new clonal cytogenetic abnormalities. Alemtuzumab can be associated with prolonged severe multilineage cytopenias, marrow hypoplasia and myelodysplasia in T-cell LPD.
Gibbs
Simon D J
SD
Haematology Service, Peter MacCallum Cancer Centre, Victoria, Australia.
Westerman
David A
DA
McCormack
Christopher
C
Seymour
John F
JF
Miles Prince
H
H
D000328:Adult; D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001854:Bone Marrow Cells / Q000473:pathology; D020732:Cytogenetic Analysis; D003586:Cytomegalovirus Infections; D020031:Epstein-Barr Virus Infections; D005260:Female; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D009503:Neutropenia; D010322:Parvoviridae Infections; D013601:T-Lymphocytes / Q000276:immunology* / Q000473:pathology; D013921:Thrombocytopenia; D014314:Trisomy
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab